Free tool
FAERS Monitor: Asclera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021201 or its brand name (Asclera, Polidocanol). Reports on generic versions are filed under their own applications.
Reports
450
Serious
263
58% of reports
Hospitalization
114
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- deep vein thrombosis35
- pain28
- pruritus28
- off label use27
- erythema26
- dizziness24
- swelling24
- injection site pain23
- pain in extremity23
- nausea22
- urticaria22
- drug ineffective20
- skin discolouration19
- pulmonary embolism18
- hypersensitivity17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 21 |
| 2014 | 6 |
| 2015 | 19 |
| 2016 | 34 |
| 2017 | 48 |
| 2018 | 64 |
| 2019 | 28 |
| 2020 | 43 |
| 2021 | 27 |
| 2022 | 46 |
| 2023 | 19 |
| 2024 | 18 |
| 2025 | 24 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,709 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| deep vein thrombosisSignal | 35 | 25.2 | 18.3 | 791 |
| skin discolourationSignal | 19 | 19.3 | 12.4 | 313 |
| swellingSignal | 24 | 12.0 | 8.1 | 232 |
| pulmonary embolismSignal | 18 | 8.9 | 5.6 | 118 |
| urticariaSignal | 22 | 6.1 | 4.1 | 90 |
| erythemaSignal | 26 | 5.9 | 4.1 | 102 |
| hypersensitivitySignal | 17 | 4.3 | 2.7 | 40 |
| pain in extremitySignal | 23 | 3.6 | 2.5 | 42 |
| injection site painSignal | 23 | 3.5 | 2.4 | 39 |
| pruritusSignal | 28 | 3.4 | 2.4 | 46 |
| dizzinessSignal | 24 | 2.2 | 1.5 | 16 |
| painSignal | 28 | 2.1 | 1.5 | 16 |
| off label use | 27 | 1.4 | 1.0 | 3 |
| nausea | 22 | 1.3 | 0.9 | 1 |
| drug ineffective | 20 | 0.7 | 0.5 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.